Jeena Sikho Lifecare Ltd.: overview

In 1947, an Indian could expect to live to thirty-two. Today it is over seventy. That gain thirty-eight years added to the average human life in the span of three generations is arguably the greatest achievement in Indian history, and almost nobody thinks of it that way.

It happened because medicine solved a specific problem with a specific method. The killers were infectious: cholera, tuberculosis, smallpox, typhoid, malaria. The method was to identify the organism, find the molecule that destroys it, and deliver that molecule to the patient. Diagnose, treat, cure, discharge. The patient arrives sick and leaves well. It worked so completely that the entire architecture of modern healthcare was built around it hospitals designed for acute intervention, drug development designed to isolate single compounds, clinical trials designed to test one variable at a time, insurance designed to reimburse discrete episodes. Then the diseases changed. Not because medicine failed but because it succeeded. People who no longer die of tuberculosis at thirty live long enough to develop diabetes at fifty.

The scale of shift from acute to chronic is difficult to hold in the mind. Over a hundred million Indians have diagnosed Type 2 diabetes and an estimated 136 million more sit in the pre-diabetic range. Around two hundred million have hypertension. Musculoskeletal disorders are the country's largest cause of disability.

Every hospital, insurer and health ministry on earth uses the World Health Organization's International Classification of Diseases to record what patients are treated for. Working with India's Ministry of AYUSH, WHO extended that system with a supplementary chapter containing diagnostic categories drawn from Ayurveda, Siddha and Unani. That single administrative act moved traditional medicine from outside the global healthcare data architecture to inside it. In India, insurance regulation now requires health insurers to cover AYUSH treatment on terms comparable to conventional care. AIIMS, the country's flagship allopathic institution, runs a Centre for Integrative Medicine and Research. More than 12,500 AYUSH-led Health and Wellness Centres operate under Ayushman Bharat.

Jeena Sikho LifeCare has spent the last several years building for that constraint rather than around it. The company runs 119 active centres across 23 states, comprising 62 inpatient hospitals and 57 clinics and day-care units, with 2,400 operational beds and 450 more in the pipeline against total built capacity of 3,031. Care is delivered through standardised operating procedures and structured physician protocols, with 51 hospitals NABH-accredited and two further in process. Its 445 formulations are manufactured in GMP-certified plants under AYUSH quality standards. Outcomes are captured in electronic medical records with structured follow-up, and clinical teams have published over 170 case reports and observational papers in peer-reviewed journals. A patient enters through consultation, may be admitted for inpatient therapy, is discharged onto a standardised formulation protocol, and returns for follow-up. Each stage feeds the next: clinical services drive medicine adoption, medicines sustain physician engagement, and the relationship persists rather than terminating at discharge. Medicine order volumes grew 167% in FY26, with patients continuing protocols at home rather than leaving after a single episode.

A patient is monetised across a sequence rather than a single visit. Content, video consultation and 72-hour camps feed OPD traffic. A portion converts into a 10–14 day Panchakarma programme. The discharged patient becomes a recurring medicines customer. Services and products therefore function as complementary revenue pools, and the same acquisition spend feeds both.

The top of the funnel is already large. Video consultations rose 121% in FY26 to 2.27 lakh and medicine orders 167% to 11.83 lakh. Third-party manufacturing keeps the product side capex-light while the hospital network supplies trust, diagnosis and repeat demand. Each new centre functions simultaneously as a treatment facility, a distribution node and a customer-acquisition channel.

Management indicates roughly ₹3–4 lakh of fit-out capex per bed for a leased Ayurveda facility, thus expansion has so far required no financial leverage. Plus FY26 cash flow from operations was about ₹262 Cr against roughly ₹34 Cr of gross capex. Financial borrowings stood at ₹0.43 Cr at year-end, with lease liabilities of about ₹134.8 Cr under Ind AS 116. The path from 2,400 beds toward the 7,000–10,000 that management has discussed over three to five years carries a total cost of roughly ₹150–200 crore, set against a business generating well above that in annual operating cash flow.

As the company expands the management deliberately is taking on less government patients. Government-panel services peaked at ₹117.8 Cr in FY25 and fell to about ₹36 Cr in FY26 as management reduced exposure to slow-paying business. The headline services mix suffered for it. Blended debtor days fell from about 66 to 32, and FY26 profit grew 177%.

What the mix change looks like at the patient level is more instructive than the revenue line. Government admissions fell from 2,052 in Q1 FY26 to 975 in Q1 FY27, a reduction of 1,077. Over the same twelve months private Panchakarma admissions rose from 8,616 to 11,500, an addition of 2,884. For every government patient released the company took on close to three private ones, and total IPD admissions still grew 17%. Government panel now represents 7.8% of IPD admissions and 5.8% of IPD revenue, against 19.2% and 18.8% a year ago.

Q1 FY27 revenue of ₹224 Cr was 29% ahead of the year-ago quarter, in line with the roughly 30% management had guided. The bridge shows what that number absorbed. Government panel subtracted ₹10.3 Cr. Every other driver added: e-commerce medicine ₹28.4 Cr, IPD Panchakarma ₹17.6 Cr, OPD medicine ₹11.8 Cr, day care ₹3.2 Cr. Set the government line aside on both sides of the comparison and revenue grew 38%.

Guidance was met on a reported basis while carrying a deliberate ₹10.3 Cr reduction.

Management is guiding to ₹1,000 Cr of profit after tax by FY30, an increase of 4x in 4years with EBITDA margins held above 40%. Jeena Sikho is now trading at a mere 27x PE on TTM basis with ROCE in excess of 60%

Alternative medicine is making a comeback, time to strengthen your portfolio immunity.

Disclaimer - Informational only. Not investment advice.
GoIndia Advisors LLP | SEBI Registered Research Analyst | Reg. No. INH000020040 | BSE Enlistment No. - 6518